Alan L. Ho

23.1k citations

191 papers · 8.2k indexed · 4 hit papers · h-index 41

Impact in

Otorhinolaryngology top 0.5%
- Head and Neck Cancer Studies
Oncology top 0.5%
- Ear and Head Tumors
- Cancer-related Molecular Pathways

Papers in

Otorhinolaryngology 29
- Head and Neck Cancer Studies 27
Oncology 94
- Ear and Head Tumors 21
- Cancer-related Molecular Pathways 19
- Cancer Immunotherapy and Biomarkers 12

Co-authors: Steven F. Dowdy Steven R. Schwarze Eric J. Sherman David G. Pfister Michelle Becker‐Hapak Sergei A. Ezhevsky Matthew G. Fury Natalie A. Lissy
Journals: Journal of Clinical Oncology (72 papers)Annals of Oncology (15 papers)Clinical Cancer Research (7 papers)International Journal of Radiation Oncology*Biology*Physics (7 papers)Cancer Research (6 papers)
Partner nations: United States United Kingdom Spain

In The Last Decade

Alan L. Ho

176 papers receiving 8.1k citations

Hit Papers

align trajectories log scale

Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma 2020 · 264 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 Journal of Clinical Oncology
2013 New England Journal of Medicine
1999 Science
1998 Nature Medicine

Peers

Countries citing papers authored by Alan L. Ho

Since Specialization

Citations

This map shows the geographic impact of Alan L. Ho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan L. Ho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan L. Ho more than expected).

Fields of papers citing papers by Alan L. Ho

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan L. Ho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan L. Ho. The network helps show where Alan L. Ho may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Alan L. Ho, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Alan L. Ho Line = papers co-authored together Alan L. Ho links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Pathologic Response to Neoadjuvant Cetuximab, Platinum, and Taxane in Locally Advanced HNSCC Otolaryngology ·Gabriel Raab, Bin Xu, S. Mukherjee Fellow Asme, Nora Katabi, Snjezana Doğan, Lara Dunn, Snehal G. Patel, Eric J. Sherman, David G. Pfister, Stephanie Tan, Felix Klingelhoefer, Ronald Ghossein, Jennifer R. Cracchiolo, Alan L. Ho, Ian Ganly, Winston Wong	2025	0
2	Exploring the potential of computer simulation models in drug testing and biomedical research: a systematic review Frontiers in Pharmacology ·Rahul Mittal, Alan L. Ho, Ali Sayed Ahmad, Oscar Valero-Sierra, Joana R. N. Lemos, 钱德春, Khemraj Hirani	2025	0
3	Sympathetic axonogenesis promotes adenoid cystic carcinoma progression The Journal of Experimental Medicine ·J.M. Paris, Paloma Ramos Ruiz, Nora Katabi, Hussein Solomon, RK Bhojani, Alan L. Ho, Luc G.T. Morris, Richard L. Bakst, Anuraag S. Parikh, Yotam Drier, Sylvie Deborde, Richard J. Wong	2025	3
4	Proton Therapy for Paranasal Sinus Cancer: Clinical Outcomes and Patterns of Failure Head & Neck ·罗桂生, Cícero Alessandro Brito Barbosa, Nadeem Riaz, Sean M. McBride, Daphna Y. Gelblum, A. Shamseddine, Marc A. Cohen, Richard J. Wong, Jennifer R. Cracchiolo, Ian Ganly, Eric J. Sherman, Alan L. Ho, Winston Wong, Lara Dunn, Anna Polunina	2025	0
5	Defining response-adapted surgery after neoadjuvant therapy in oral cavity cancer Oral Oncology ·Jennifer R. Cracchiolo, Azka Layalia Asandri, Richard J. Wong, Alan L. Ho, Ian Ganly, David G. Pfister, Nancy Y. Lee, Winston Wong, Stephanie Tan, Marc A. Cohen, Lara Dunn	2025	2
6	A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer Oral Oncology ·Antoine Desîlets, David G. Pfister, Sarah Stein, Winston Wong, Eric J. Sherman, James Fetten, Karla Elizabeth Velasco, Anuja Kriplani, Lara Dunn, Alan L. Ho, Loren S. Michel	2024	4
7	868P Phase II trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) Annals of Oncology ·W. Douglas Wong, Y Nasir, Ernest Lepointe, Hélio A Souza, Jaspreet Singh Grewal, James Russell, Jeremy Cetnar, Alan L. Ho, Ken Chen, Kartik Aysola, Jacob Thomas	2024	3
8	921P HB-200 arenavirus-based immunotherapy plus pembrolizumab as a first-line treatment of patients with recurrent/metastatic HPV16 positive head and neck cancer Annals of Oncology ·Lisle M. Nabell, Alan L. Ho, Marshall R. Posner, Andrew Butler, Ayelén Ledesma, Stuart J. Wong, Jiaxin Niu, Alexander T. Pearson, Douglas Laux, Douglas R. Adkins, Maria Sternemann, Ari J. Rosenberg, Debra L. Richardson, W. Douglas Wong, B C Vishwas, Kianoosh Katchar, Qing Xin, Wendy Vanesa Ricardo Benitez, Katia Schlienger, David G. Pfister	2023	3
9	Loss of CDKN2A/B is a Molecular Marker of High-grade Histology and is Associated with Aggressive Behavior in Acinic Cell Carcinoma Modern Pathology ·Snjezana Doğan, Bin Xu, Satshil Rana, Hui Chen, Ronald Ghossein, Michael F. Berger, Alan L. Ho, Nora Katabi	2023	14
10	Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA) Journal of Clinical Oncology ·Alan L. Ho, Marek Dedecjus, Lori J. Wirth, R. Michael Tuttle, William B. Inabnet, Jan Tennvall, Fernanda Vaisman, Lars Bastholt, Andrew G. Gianoukakis, Patrice Rodien, Ralf Paschke, Rossella Elisei, David Viola, Karen So, Danielle Carroll, Somia BENCHIKH, Hugo Hildebrandt, James A. Fagin, (unknown)	2022	37
11	ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing Modern Pathology ·Donna C. Ferguson, Amir Momeni Boroujeni, Tao Zheng, Abhinita Mohanty, Alan L. Ho, Maria E. Arcila, Dara S. Ross, Snjezana Doğan	2021	10
12	Diagnostic discrepancy in second opinion reviews of primary epithelial neoplasms involving salivary gland: An 11‐year experience from a tertiary referral center focusing on useful pathologic approaches and potential clinical impacts Head & Neck ·Bin Xu, Ronald Ghossein, Alan L. Ho, Kartik Viswanathan, G. Doros, Maelle Saliba, Jennifer R. Cracchiolo, Nora Katabi	2021	3
13	The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype Clinical Cancer Research ·Maximilian Linxweiler, Fengshen Kuo, Nora Katabi, Mark Lee, Zaineb Nadeem, Martin G. Dalin, Vladimir Makarov, Diego Chowell, Snjezana Doğan, Ian Ganly, A. Ari Hakimi, Richard J. Wong, Nadeem Riaz, Alan L. Ho, Timothy A. Chan, Luc G.T. Morris	2020	79
14	Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma Journal of Clinical Oncology ·Sean M. McBride, Eric J. Sherman, C. Jillian Tsai, Shrujal S. Baxi, Jahan Aghalar, Juliana Eng, Wanqing Iris Zhi, Daniel C. McFarland, Loren S. Michel, Robert J. Young, Robert A. Lefkowitz, D. Spielsinger, Zhigang Zhang, Jessica Flynn, Lara Dunn, Alan L. Ho, Nadeem Riaz, David G. Pfister, Nancy Y. Lee Hit paper breakdown →	2020	264
15	Distant metastasis of salivary gland cancer: Incidence, management, and outcomes Cancer ·李巨澜, Marlena McGill, Ashley Hay, Daniella K. Zanoni, Jatin P. Shah, Richard J. Wong, Alan L. Ho, Marc A. Cohen, Snehal G. Patel, Ian Ganly	2020	40
16	Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer Clinical Cancer Research ·Martin G. Dalin, Alexis Desrichard, Nora Katabi, Vladimir Makarov, Logan A. Walsh, Ken-Wing Lee, Qingguo Wang, Joshua Armenia, Lyndsay West, Snjezana Doğan, Lu Wang, Deepa Ramaswami, Alan L. Ho, Ian Ganly, David B. Solit, Michael F. Berger, Nikolaus Schultz, Jorge S. Reis‐Filho, Timothy A. Chan, Luc G.T. Morris	2016	135
17	Apparent speed of a rotating disk varies with texture density Journal of Vision ·Stuart Anstis, Alan L. Ho	2014	3
18	Inhibition of Mutant GNAQ Signaling in Uveal Melanoma Induces AMPK-Dependent Autophagic Cell Death Molecular Cancer Therapeutics ·Grazia Ambrosini, Elgilda Musi, Alan L. Ho, Elisa de Stanchina, Gary K. Schwartz	2013	85
19	PTEN regulates sensitivity of melanoma cells to RO4929097, the γ-secretase inhibitor. PubMed ·Jayasree S. Nair, Tahir Sheikh, Alan L. Ho, Gary K. Schwartz	2013	28
20	PDGF Receptor Alpha Is an Alternative Mediator of Rapamycin-Induced Akt Activation: Implications for Combination Targeted Therapy of Synovial Sarcoma Cancer Research ·Alan L. Ho, Shyamprasad Deraje Vasudeva, Marick Laé, Tsuyoshi Saito, Violetta Barbashina, Cristina R. Antonescu, Marc Ladanyi, Gary K. Schwartz	2012	56

About Alan L. Ho

Alan L. Ho is a scholar working on Otorhinolaryngology, Oncology, Endocrinology, Diabetes and Metabolism, Pulmonary and Respiratory Medicine and Surgery, having authored 191 papers that have together received 8.2k indexed citations. Recurring topics across this work include Salivary Gland Tumors Diagnosis and Treatment (49 papers), Thyroid Cancer Diagnosis and Treatment (36 papers), Head and Neck Cancer Studies (27 papers), Lung Cancer Treatments and Mutations (25 papers), Ear and Head Tumors (21 papers), Cancer-related Molecular Pathways (19 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Radiopharmaceutical Chemistry and Applications (11 papers). The work is most often cited by research in Otorhinolaryngology (494 citations), Oncology (2.8k citations), Molecular Biology (4.2k citations), Endocrinology, Diabetes and Metabolism (983 citations) and Oral Surgery (333 citations). Alan L. Ho has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Steven F. Dowdy, Steven R. Schwarze, Eric J. Sherman, David G. Pfister, Michelle Becker‐Hapak, Sergei A. Ezhevsky, Matthew G. Fury, Natalie A. Lissy, Hikaru Nagahara and Nora Katabi. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Clinical Cancer Research, International Journal of Radiation Oncology*Biology*Physics and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact